Dentsply Sirona has acquired Datum Dental, which produces the OSSIX line of biomaterials. Also, Datum Dental is known for its dental regeneration products and its GLYMATRIX proprietary technology, Dentsply Sirona said.
Datum Dental complements Dentsply Sirona’s existing implant dentistry strategy around Ankylos, Astra Tech Implant System, Xive, and Atlantis, Dentsply Sirona said. In addition, Dentsply Sirona noted many promising products in Datum Dental’s strong R&D pipeline.
The acquisition, then, will open up significant opportunities within Dentsply Sirona’s implants segment, the company said. Driven by the GLYMATRIX core technology, Dentsply Sirona said, OSSIX’s bio-durable design will ensure long-term predictable and superior results.
“Datum Dental perfectly fits in our strategy to deliver innovative and meaningful solutions for our customers. The biomaterial sector is an important cornerstone of the future of dentistry,” said Gene Dorff, vice president of the implants product group at Dentsply Sirona.
“The acquisition is another important step for us to deliver on our purpose to empower dental professionals to provide patients with better dental care and make people smile,” said Dorff.
“We are pleased that the OSSIX family is becoming part of the market leader in dental. Dentsply Sirona offers us opportunities to work on continued innovation with the strongest R&D team in the industry,” said Itay Itzhaky, chief executive officer of Datum Dental.
“Our R&D pipeline will continue to develop new, safe, and transformational solutions that simplify procedures and overcome major deficiencies in existing biomaterial-based regenerative products,” said Itzhaky.
Dentsply Sirona has had distribution agreements with Datum Dental since 2016. It is now promoting the full OSSIX portfolio in the United States, Canada, Columbia, France, Belgium, UK-Ireland, Nordics, Poland, Romania, Turkey, and Hong Kong.
Clinicians will benefit from the implementation of OSSIX products in a broad set of solutions and workflows and from Dentsply Sirona’s capacity to invest in future development, the company said. The OSSIX portfolio will be the foundation of Dentsply Sirona’s regenerative portfolio.
The acquisition is expected to close in January 2021 following customary approval requirements.
Related Articles
OSSIX Bone Cleared for Use in Canada and Europe
A “Graft Less” Approach to Posterior Implant Sites
